CYCN — Cyclerion Therapeutics Cashflow Statement
0.000.00%
- $10.09m
- $6.86m
- $2.00m
- 26
- 32
- 64
- 35
Annual cashflow statement for Cyclerion Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -77.8 | -51.6 | -44.1 | -5.26 | -3.06 |
Depreciation | |||||
Non-Cash Items | 10.6 | 13.3 | 6.25 | -11.4 | 0.262 |
Discontinued Operations | |||||
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -7.59 | 1.41 | -2.85 | -4.6 | -1.54 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Cash from Operating Activities | -72.5 | -36.5 | -40.6 | -21.2 | -4.33 |
Capital Expenditures | -1.52 | -0.007 | 0 | — | — |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 1.54 | 1.46 | 0 | 10.4 | 0 |
Sale of Fixed Assets | |||||
Cash from Investing Activities | 0.018 | 1.46 | 0 | 10.4 | 0 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 28.1 | 30.8 | 0.029 | 5.02 | 0 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -44.4 | -4.27 | -40.6 | -5.81 | -4.34 |